Open the filing on EDGARAmbiq Reports First Quarter 2026 Financial Results
First quarter net sales exceeded guidance, increasing 59.3% year-over-year on expanding demand for edge AI
GAAP gross margin was 43.5%; non-GAAP gross margin was 46.2%, reflecting improved manufacturing efficiencies
Expect strong second quarter net sales of $31.0 million to $32.0 million, driven by continued edge AI demand momentum and strong execution
AUSTIN, Texas, May 12, 2026 - Ambiq Micro, Inc. (“Ambiq”) (NYSE: AMBQ), a technology leader in ultra-low-power semiconductor solutions for edge AI, today announced financial results for the first quarter 2026.
First Quarter 2026 Highlights
Exceptional start to 2026 with accelerating demand momentum: Delivered strong first quarter net sales, increasing year-over-year and sequentially. This reflects strong demand for edge AI solutions, expanding customer adoption of Ambiq products and upgrades to higher-value Apollo platforms, with more than 80% of units shipped running AI algorithms.
Manufacturing efficiency supports profitability: Gross margin performance reflects optimized production processes, helping to offset industry-wide cost pressures.
Expanded customer and end market diversification: In first quarter 2026, the Company's top three customers accounted for approximately 71% of net sales, compared to 86% in first quarter 2025. For the full year, net sales outside of personal devices is expected to double in 2026 compared to 2025.
Continued recognition as edge AI innovator: Won the 2026 Embedded World Award in the Best Tools category for heliaAOT™, its ahead-of-time AI compiler, marking the third consecutive year of recognition and reinforcing Ambiq’s leadership in ultra-low-power edge AI solutions.
Breakthrough in ultra-low-power semiconductor platform development: Revealed its 12nm SPOT® platform powering the upcoming Atomiq® SoC, enabling operation down to 300mV, the lowest voltage in Company history, and advancing energy-efficient performance for next-generation edge AI devices.
Expansion of global R&D footprint to accelerate edge AI innovation: Announced a multi-year Singapore-based R&D program, supported by the Economic Development Board, to advance next-generation edge AI technologies and expand development and licensing of its SPOT® platform.
Management Commentary
“We have started 2026 with exceptional momentum, delivering strong results driven by accelerating demand for edge AI capabilities and strong execution. Our differentiated, ultra-low power SPOT platform positions us as the partner of choice for enabling on-device intelligence as we expand our presence across a broader range of form factors, use cases, customers and end markets,” said Fumihide Esaka, CEO of Ambiq. “With established technology leadership, positive demand trends, and a robust product roadmap, we remain confident in our ability to drive durable top-line growth and margin expansion in the years ahead.”
Summary of First Quarter 2026 Results
| GAAP (Unaudited; $ in thousands) | Three months ended March 31, | Three months ended December 31, | Three months ended March 31, | Quarter over quarter change | Year over year change |
| 2026 | 2025 | 2025 | | |
| Net sales | $25,060 | $20,744 | $15,732 | 20.8% | 59.3% |
| Gross profit | $10,891 | $8,859 | $8,389 | 22.9% | 29.8% |
| Gross margin | 43.5% | 42.7% | 53.3% | 0.8 pts | -9.8 pts |
| Operating expense | $22,580 | $20,821 | $17,130 | 8.4% | 31.8% |
| Net loss | $(10,171) | $(10,679) | $(8,284) | $508 | $(1,887) |
| NON-GAAP FINANCIAL MEASURES* (Unaudited; $ in thousands) | Three months ended March 31, | Three months ended December 31, | Three months ended March 31, | Quarter over quarter change | Year over year change |
| 2026 | 2025 | 2025 | | |
| Non-GAAP Gross profit | $11,577 | $9,436 | $7,412 | 22.7% | 56.2% |
| Non-GAAP Gross margin | 46.2% | 45.5% | 47.1% | 0.7 pts | -0.9 pts |
| Non-GAAP Operating expense | $18,144 | $16,599 | $13,148 | 9.3% | 38.0% |
| Non-GAAP Net loss | $(5,046) | $(5,861) | $(5,217) | $815 | $171 |
*Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expense and non-GAAP net loss are non-GAAP financial measures. See "Non-GAAP Financial Measures" below for definitions of each of these measures, and the tables accompanying this press release for reconciliations of these measures to their most comparable GAAP measure.
Second Quarter Business Outlook
Ambiq’s current expectations for the quarter ending June 30, 2026, include the following:
Net sales within a range of $31.0 million to $32.0 million
Non-GAAP gross margin between 45.0% and 46.0%
Non-GAAP operating expense of $21.0 million to $22.0 million
Non-GAAP net loss per share within a range of ($0.29) to ($0.23) based on a weighted average share count of 21.38 million shares outstanding
Ambiq's financial outlook is based on assumptions that it believes to be reasonable as of the date of this release, but may be materially affected by many factors, as discussed below in "Forward-Looking Statements." Actual results may vary from the guidance and the variations may be material. We undertake no intent or obligation to publicly update or revise this outlook, whether as a result of new information, future events or otherwise, except as required by law. The Company is unable to include a reconciliation of forward-looking non-GAAP net loss per share, non-GAAP gross margin and non-GAAP operating expense to the most directly comparable GAAP measure without unreasonable effort due to the high variability with respect to the impact of items such as depreciation and amortization and, stock-based compensation expense and other items that are excluded from these non-GAAP measures.
Conference Call
Ambiq will host a conference call for analysts and investors today at 8:30 a.m. Eastern Time. Interested participants can access the call by dialing 1-833-461-5787 and providing conference ID 507165301. International callers may join the call by dialing +1-585-542-9983, using the same code. The call will also be available as a live and archived webcast on the Events & Presentations section of Ambiq's Investor Relations website.
About Ambiq Micro
Headquartered in Austin, Texas, Ambiq's mission is to enable intelligence (artificial intelligence (AI) and beyond) everywhere by delivering the lowest power semiconductor solutions. Ambiq enables its customers to deliver AI compute at the edge where power consumption challenges are the most severe. Ambiq's technology innovations, built on the patented and proprietary subthreshold power optimized technology (SPOT®), fundamentally deliver a multi-fold improvement in power consumption over traditional semiconductor designs. Ambiq has powered over 300 million devices to date. For more information, visit www.ambiq.com.
Non-GAAP Financial Measures
Ambiq supplements its reporting of financial information determined under generally accepted accounting principles in the United States of America (GAAP), including the use of non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP R&D expenses, non-GAAP SG&A expenses and non-GAAP net loss. These non-GAAP financial measures help management make strategic decisions, establish budgets and operational goals for managing the business, analyzing financial results, and evaluating business performance. Ambiq defines non-GAAP gross profit as gross profit adjusted to exclude expenses not directly attributable to gross profit, such as depreciation and amortization, stock-based compensation and gain on nonmonetary transaction. Ambiq defines non-GAAP gross margin as non-GAAP gross profit as a percentage of net sales. Ambiq defines non-GAAP operating expenses, non-GAAP R&D expenses and non-GAAP SG&A expenses as operating expenses, R&D expenses and SG&A expenses, as applicable, adjusted to exclude expenses not directly attributable to operating expenses, R&D expenses and SG&A expenses, as applicable, such as depreciation and amortization, stock-based compensation, severance costs, IPO-related bonus and IPO and other transaction costs, as applicable. Ambiq defines non-GAAP net loss as net loss adjusted to exclude expenses not directly attributable to the performance of operations, such as income taxes, depreciation and amortization, stock-based compensation, gain on nonmonetary transaction, severance costs, IPO-related bonus, IPO and other transaction costs and warrant valuation.
Ambiq believes these non-GAAP financial measures provide additional tools for investors to use in comparing core business and results of operations over multiple periods with other companies in the industry, many of which present similar non-GAAP financial measures. However, Ambiq's presentation of non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP R&D expenses, non-GAAP SG&A expenses, and non-GAAP net loss may not be comparable to similarly titled measures reported by other companies due to differences in the way that these measures are calculated. These non-GAAP measures have limitations, and should not be considered as the sole measures of our performance and should not be considered in isolation from, or as a substitute for, the most comparable measure calculated in accordance with GAAP.
Forward-Looking Statements
Forward-looking statements notice
The statements contained in this press release that are not historical facts are forward-looking statements. You can identify forward-looking statements because they contain words such as "believes," "expects," "may," "will," "should," "seeks," "intends," "plans," "estimates," or "anticipates," or similar expressions which concern our strategy, plans, projections or intentions. These forward-looking statements may be included throughout this press release, and include, but are not limited to, statements relating to Ambiq's expectations around its strategic initiatives, growth trajectory and expected second quarter business and full year outlook. By their nature, forward-looking statements are not statements of historical fact or guarantees of future performance and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify including those described in the section titled "Risk Factors" in Ambiq's Annual Report on 10-K for the year ended December 31, 2025, as well as in other filings Ambiq may make with the SEC in the future. Ambiq's expectations, beliefs and projections are expressed in good faith and Ambiq believes there is a reasonable basis for them. However, there can be no assurance that management's expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this release. Ambiq undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
CONSOLIDATED BALANCE SHEETS
(Unaudited and in thousands, except share and per share amounts)
| March 31, | December 31, |
|---|
| 2026 | 2025 |
|---|
| Assets | | |
| Current assets: | | |
| Cash and cash equivalents | $204,535 | $140,275 |
| Accounts receivable, net | 10,975 | 7,286 |
| Inventories | 23,463 | 16,937 |
| Prepaid expenses and other current assets | 2,688 | 3,421 |
| Total current assets | $241,661 | $167,919 |
| Property, equipment and software, net of accumulated depreciation and amortization of $15,051 and $14,632, respectively | 4,322 | 4,137 |
| Right-of-use assets, net | 1,682 | 638 |
| Intangible assets, net of accumulated amortization of $12,090 and $10,752, respectively | 11,465 | 11,593 |
| Other assets | 391 | 393 |
| Total assets | $259,521 | $184,680 |
| Liabilities and stockholders’ equity | | |
| Current liabilities: | | |
| Accounts payable | $8,285 | $8,577 |
| Accrued and other current liabilities | 11,380 | 10,201 |
| Short-term lease liabilities | 982 | 400 |
| Total current liabilities | $20,647 | $19,178 |
| Long-term lease liabilities | 1,161 | 278 |
| Other long-term liabilities | 2,554 | 2,765 |
| Total liabilities | $24,362 | $22,221 |
| Commitments and contingencies (Note 6) | | |
| Stockholders’ equity: | | |
| Common stock, $0.000001 par value; 500,000,000 shares authorized; 21,359,204 shares and 18,316,928 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | - | - |
| Additional paid-in-capital | 602,416 | 519,610 |
| Accumulated deficit | (366,882) | (356,711) |
| Accumulated other comprehensive loss | (375) | (440) |
| Total stockholders’ equity | 235,159 | 162,459 |
| Total liabilities and stockholders’ equity | $259,521 | $184,680 |
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited and in thousands, except share and per share amounts)
| March 31, 2026 | March 31, 2025 |
|---|
| Net sales | $25,060 | $15,732 |
| Cost of sales | 14,169 | 7,343 |
| Gross profit | 10,891 | 8,389 |
| Operating expenses: | | |
| Research and development | 12,832 | 8,687 |
| Selling, general, and administrative | 9,748 | 8,443 |
| Total operating expenses | 22,580 | 17,130 |
| Loss from operations | (11,689) | (8,741) |
| Other income, net | 1,521 | 461 |
| Loss before income taxes | (10,168) | (8,280) |
| Provision for income taxes | 3 | 4 |
| Net loss | $(10,171) | $(8,284) |
| Net loss per share, basic and diluted | $(0.50) | $(18.96) |
| Weighted-average shares used in computing net loss per share, basic and diluted | 20,396,354 | 436,890 |
| Comprehensive loss: | | |
| Currency translation adjustment | 65 | (30) |
| Comprehensive loss | $(10,106) | $(8,314) |
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited and in thousands)
| For the three months ended March 31, |
|---|
| 2026 | 2025 |
|---|
| Cash flows from operating activities | | |
| Net loss | $(10,171) | $(8,284) |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | | |
| Depreciation and amortization | 1,740 | 1,961 |
| Stock-based compensation | 3,362 | 851 |
| Gain on receipt of nonmonetary tangible assets | - | (1,600) |
| Change in right-of-use assets | 209 | 242 |
| Change in warrant valuations and cancellations | - | (58) |
| Changes in operating assets and liabilities | | |
| Accounts receivable | (3,644) | 6,349 |
| Inventories | (6,526) | (286) |
| Prepaid expenses and other assets | 745 | 66 |
| Other long-term assets | (3) | - |
| Accounts payable | 2,142 | 2,255 |
| Accrued and other current liabilities | 885 | (90) |
| Other long-term liabilities | 88 | - |
| Net cash (used in) provided by operating activities | (11,173) | 1,406 |
| Cash flows from investing activities | | |
| Purchase of intangible assets | (3,437) | (1,000) |
| Purchases of property, equipment and software | (584) | (116) |
| Net cash used in investing activities | (4,021) | (1,116) |
| Cash flows from financing activities | | |
| Proceeds from issuance of common stock in connection with follow-on offering, net of underwriting discounts and commissions | 76,832 | - |
| Payment of deferred offering costs | (1,488) | - |
| Proceeds from exercise of stock options | 1,090 | 148 |
| Proceeds from exercise of warrants | 3,010 | - |
| Net cash provided by financing activities | 79,444 | 148 |
| Effect of exchange rate changes on cash and cash equivalents | 10 | (1) |
| Net increase in cash and cash equivalents | 64,260 | 437 |
| Cash and cash equivalents at beginning of period | 140,275 | 60,981 |
| Cash and cash equivalents at end of period | $204,535 | $61,418 |
| Supplemental disclosure of non-cash investing and financing activities | | |
| Intangible assets in accounts payable, accrued and other long-term liabilities | 7,536 | 6,004 |
| Gain on receipt of nonmonetary tangible asset | - | 1,600 |
| Right-of-use assets obtained in exchange for new operating lease liabilities | 1,237 | 383 |
The following table reconcile the most directly comparable GAAP financial measure to each of these non-GAAP financial measures.
Non-GAAP Net Loss:
| Three months ended March 31, | Three months ended December 31, |
|---|
| 2026 | 2025 | 2025 |
|---|
| (in thousands) |
|---|
| Net loss | $(10,171) | $(8,284) | $(10,679) |
| Add: | | | |
| Income taxes | 3 | 4 | 19 |
| Depreciation and amortization | 1,740 | 1,961 | 1,648 |
| Stock-based compensation | 3,362 | 851 | 3,151 |
| Gain on nonmonetary transaction | - | (1,600) | - |
| Severance costs | 20 | - | - |
| IPO and other transaction costs | - | 1,793 | - |
| Warrant valuation | - | 58 | - |
| Non-GAAP net loss | $(5,046) | $(5,217) | $(5,861) |
Non-GAAP Gross Profit and Non-GAAP Gross Margin:
| Three months ended March 31, | Three months ended December 31, |
|---|
| 2026 | 2025 | 2025 |
|---|
| Gross profit | $10,891 | $8,389 | $8,859 |
| Add: | | | |
| Depreciation and amortization | 499 | 562 | 475 |
| Stock-based compensation | 187 | 61 | 102 |
| Gain on nonmonetary transaction | - | (1,600) | - |
| Non-GAAP gross profit | $11,577 | $7,412 | $9,436 |
Non-GAAP Operating Expenses:
| Three months ended March 31, | Three months ended December 31, |
|---|
| 2026 | 2025 | 2025 |
|---|
| (in thousands) |
|---|
| Operating expenses | $22,580 | $17,130 | $20,821 |
| Less: | | | |
| Depreciation and amortization | 1,241 | 1,399 | 1,173 |
| Stock-based compensation | 3,175 | 790 | 3,049 |
| Severance | 20 | - | - |
| IPO and other transaction costs | - | 1,793 | - |
| Non-GAAP operating expenses | $18,144 | $13,148 | $16,599 |
| Three months ended March 31, | Three months ended December 31, |
|---|
| Research and development | 2026 | 2025 | 2025 |
| (in thousands) | |
| Operating expenses | $12,832 | $8,687 | $12,012 |
| Less: | | | |
| Depreciation and amortization | 1,202 | 1,257 | 1,136 |
| Stock-based compensation | 1,518 | 389 | 1,609 |
| Severance | 20 | - | - |
| Non-GAAP operating expenses | $10,092 | $7,041 | $9,268 |
| Three months ended March 31, | Three months ended December 31, |
|---|
| Selling, general, and administrative | 2026 | 2025 | 2025 |
| (in thousands) | |
| Operating expenses | $9,748 | $8,443 | $8,809 |
| Less: | | | |
| Depreciation and amortization | 39 | 142 | 37 |
| Stock-based compensation | 1,657 | 401 | 1,440 |
| IPO and other transaction costs | - | 1,793 | - |
| Non-GAAP operating expenses | $8,052 | $6,107 | $7,331 |
Non-GAAP Net Loss per Share:
| Three months ended March 31, |
|---|
| 2026 | 2025 |
|---|
| GAAP net loss | $(10,171) | $(8,284) |
| Weighted-average shares used in computing GAAP net loss per share | 20,396,354 | 436,890 |
| GAAP net loss per share | $(0.50) | $(18.96) |
| Non-GAAP net loss | $(5,046) | $(5,217) |
| Weighted-average shares used in computing non-GAAP net loss per share | 20,396,354 | 436,890 |
| Non-GAAP net loss per share | $(0.25) | $(11.94) |
Company Contact Charlene Wan VP of Corporate Marketing cwan@ambiq.com Investor Relations Contact Teneo Christina Coronios christina.coronios@teneo.com